We found that TEAD1 expression was significantly associated with higher clinical stages of multiple cancers, including adrenocortical carcinoma (ACC), BLCA, head and neck squamous cell carcinoma (HNSC), and kidney renal clear cell carcinoma (KIRC) (Supplementary Figures 1A–L). This evidence concerns the gene TEAD1 and bladder transitional cell carcinoma.